Verkazia Approved for Vernal Keratoconjunctivitis
The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC.
The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC.
Ischemic optic neuropathies are the most common acute optic nerve pathology in patients older than 50 years of age.
Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, shows how new options in glaucoma management can help ophthalmology overcome patient noncompliance.
Previously unrecognized pathogenic mechanisms involving ocular contact dermatitis has driven new approaches to control the inflammatory process.
Recent guidelines are designed to optimize uveitis screening protocols for pediatric patients.
EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.
Deep learning has shown substantial promise to date in automated image analysis towards the accurate diagnosis of diabetic retinopathy.
The Food and Drug Administration (FDA) has approved Avaclyr (acyclovir ophthalmic ointment; Fera Pharmaceuticals) 3% for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
Researchers at The Ohio State University have announced the development of the first chimeric mouse model of Sjögren’s syndrome—giving scientists an unprecedented look at the progression of the debilitating “dry eye” disease.
Glaucoma, the second-leading cause of blindness in the world, is a condition that occurs when too much pressure builds up inside the eye. This excess pressure pushes back against blood trying to enter the eye, resulting in vision loss.